XML 53 R43.htm IDEA: XBRL DOCUMENT v3.25.3
Balance Sheet Components - Intangible Assets, Net (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Finite-lived assets, net $ 20,625,000     $ 20,625,000   $ 24,787,000
Accumulated amortization 4,375,000     4,375,000   2,719,000
Indefinite-lived assets - in-process research and development 28,859,000     28,859,000   28,859,000
Total Intangible assets, net 49,484,000     49,484,000   $ 53,646,000
Amortization expense, Finite-lived intangible assets 700,000 $ 1,100,000   2,000,000 $ 2,700,000  
Impairment of out-license asset and remeasurement of CVR liability, net       1,646,000 $ 6,772,000  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]     Selling, General and Administrative Expense      
Impairment charge       0    
Novartis Institutes | Surface Acquisition            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Finite-lived assets, net     $ 10,600,000      
Impairment of out-license asset and remeasurement of CVR liability, net     6,800,000      
Fair value of the contingent consideration     3,800,000      
Fair value     $ 0      
GlaxoSmithKline Intellectual Property No. 4 Limited ("GSK") | Surface Acquisition            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Finite-lived assets, net 1,600,000     1,600,000    
Impairment of out-license asset and remeasurement of CVR liability, net 500,000          
Impairment charge 2,100,000          
Fair value $ 0     $ 0